Tetracyclic indole derivatives as antiviral agents

(74) Agent: MAN, Jocelyn; Merck & Co., Inc, European Patent Department, Terlings Park, Eastwick Road, Harlow Essex CM20 2QR (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (88) Date of publication of the international search report:

July 2006

For two-letter codes and other abbreviations, refer to the Guidance Notes on Codes and Abbreviations appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS

<img file="AU2005298412B2_D0001.tif" />

(57) Abstract: The present invention relates to tetracyclic indole compounds of formula (I); wherein R¹, R², R^U, R¹⁵, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

2005298412 11 May 2011

Tetracyclic indole derivatives as antiviral agents

The present invention relates to tetracyclic indole compounds, to pharmaceutical compositions containing them, to their use in the prevention and treatment of hepatitis C infections and to methods of preparation of such compounds and compositions.

Hepatitis C (HCV) is a cause of viral infections. There is as yet no adequate treatment for HCV infection but it is believed that inhibition of its RNA polymerase in mammals, particularly humans, would be of benefit.

Published International patent application WO 93/00334 (Fidia-Georgetown Institute for the Neurosciences) discloses the following indole derivatives:

<img file="AU2005298412B2_D0002.tif" />

where A, Z, Ri, R₂, R3, R4 and n are defined therein, as useful in compositions and methods for treating psychiatric and neurological disorders. However, this document does not disclose the use of tetracyclic indole derivatives in treating or preventing viral infections.

Published International patent application WO 2005/080399 (Japan

Tobacco Inc.) discloses the following fused heterotetracyclic compounds:

<img file="AU2005298412B2_D0003.tif" />

where A, X, Cy, G¹, G², G³, G⁴, G⁵, G⁶, R¹, R², R³, R⁴, R⁵, R⁶ and a are defined therein, and their use as HCV polymerase inhibitors.

(4286494 1):K2A la

2005298412 11 May 2011

A first aspect of the invention provides for a compound of formula (lb) or a pharmaceutically acceptable salt thereof:

<img file="AU2005298412B2_D0004.tif" />

(lb) wherein

R¹⁰ is hydrogen, C,.₆alkyl, C₂^alkenyl, or (CH₂)i.₃NR¹⁶R¹⁷;

R¹⁶ and R¹⁷ are independently selected from hydrogen and Ci-ealkyl; and

R^14a and R^15a are independently selected from hydrogen, Ci^alkyl, or C₂.6alkenyl.

A second aspect of the invention provides for a compound of formula (Ic) or a io pharmaceutically acceptable salt thereof:

<img file="AU2005298412B2_D0005.tif" />

(ic) wherein

R¹⁰ is hydrogen, Ci^alkyl, or C₂.6alkenyl;

R¹⁴ and R¹⁵ are independently selected from hydrogen, Chalky!, C₂.6alkenyl, or is (CH₂)o.₃NR^I6R¹⁷; and

R¹⁶ and R¹⁷ are independently selected from hydrogen and Ci^alkyl.

(4286494 l)KZA

2005298412 11 May 2011 lb

A third aspect of the invention provides for a compound selected from the group consisting of:

14-cyclohexyl-5-[2-(dimethylamino)ethyl]-5,6,7,8-tetrahydroindolo[ 1,2e][l,5]benzodiazocine-l 1-carboxylic acid,

14-cyclohexyl-5-methyl-5,6,7,8-tetrahydroindolo[ 1,2-e][ 1,5]benzodiazocine-1J carboxylic acid, and

14-cyclohexyl-7-(dimethylamino)-5-methyl-5,6,7,8-tetrahydroindolo[ 1,2e] [ 1,5]benzodiazocine-11 -carboxylic acid, or a pharmaceutically acceptable salt thereof.

io A fourth aspect of the invention provides for a compound as claimed in any one of the first, second or third aspects of the invention or a pharmaceutically acceptable salt thereof for use in therapy.

A fifth aspect of the invention provides for a use of a compound of any one of the first, second or third aspects of the invention, or a pharmaceutically acceptable salt is thereof, for the manufacture of a medicament for treatment or prevention of infection by hepatitis C virus in a human or animal.

A sixth aspect of the invention provides for a composition comprising a compound of any one of the first, second or third aspects of the invention, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically 20 acceptable carrier.

A seventh aspect of the invention provides for a method of inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical 25 composition of the sixth aspect of the invention or of a compound of any one of the first, second or third aspects of the invention, or a pharmaceutically acceptable salt thereof.

An eighth aspect of the invention provides for a method of preparation of a pharmaceutical composition, involving admixing at least one compound of any one of the first, second or third aspects of the invention, or a pharmaceutically acceptable salt 30 thereof, with one or more pharmaceutically acceptable adjuvants, diluents or carriers and/or with one or more other therapeutically or prophylactically active agents.

Disclosed herein is the compound of the formula (I):

(4286494 1):KZA

WO 2006/046039

PCT/GB2005/004144

<img file="AU2005298412B2_D0006.tif" />

<img file="AU2005298412B2_D0007.tif" />

A (D wherein

A is C₃.₈cycloalkyl, optionally substituted by halogen, hydroxy, Chalky! or Ci.₄alkoxy;

Ar is a moiety containing at least one aromatic ring and possesses 5, 6, 9 or 10 ring atoms, optionally containing 1, 2 or 3 heteroatoms independently selected from N, O and S, such as phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, furanyl, pyrazolyl and imidazolyl, which ring is optionally substituted by groups Q¹ and Q²;

Q¹ is halogen, hydroxy, Cj.6alkyl, Ci.6alkoxy, (CH2)0.3aryl, heteroaryl, CONR^cR^d, (CH2)₀.₃NR^cR^d, O(CH2)0.3C3.8cycloalkyl, O(CH2)0.3CONR^cR^d, O(CH2)₀.₃CO₂H, 0(CH₂)o-₃aryl,

O(CH₂)₀.₃heteroaryl, OCHR^eR^f or O(CH₂)₀-₃S(O)₂(CH₂)₀.₃NR^cR^d;

R^c and R^d are independently selected from hydrogen, Chalky! and C(O)Ci.₆alkyl;

or R^c and R^d, together with the nitrogen atom to which they are attached, form a heteroaliphatic ring of 4 to 7 ring atoms, optionally containing 1 or 2 more heteroatoms independently selected from O and S and/or 1 or 2 groups independently selected from NH and NCi^alkyl, where said ring is optionally substituted by halogen, hydroxy, Ci.₄alkyl or Ci.₄alkoxy;

R^e and R^f are independently selected from hydrogen, Ci.₄alkyl and Ci.₄alkoxy;

or R^e and R^f are linked by a heteroatom selected from N, O and S to form a heteroaliphatic ring of 4 to 7 ring atoms, where said ring is optionally substituted by halogen, hydroxy, Ci.₄alkyl or Ci.₄alkoxy;

and where said Cj.₄alkyl, Ci.₄alkoxy and aryl groups are optionally substituted by halogen or hydroxy;

Q² is halogen, hydroxy, Cj.₄alkyl or Ci.₄alkoxy, where said Ci.₄alkyl and C].₄alkoxy groups are optionally substituted by halogen or hydroxy;

or Q¹ and Q² may be linked to form a ring of 4 to 7 atoms, where said ring optionally contains 1 or 2 heteroatoms independently selected from N, O and S, and is optionally substituted by halogen, hydroxy, C].₄alkyl or Ci.₄alkoxy;

one of R¹ and R² is CO2H, C(O)NHS(O)2NR^aR^b, C(O)NHS(O)2C₁.₆alkyl, C(O)NHS(O)₂(CH₂)₀.₃CO₂R^c or C(O)NHS(O)₂(CH₂)₀.₃aryl, and the other of R¹ and R² is hydrogen;

R^a and R^b are independently selected from hydrogen and Chalky!, or R^a and R^b, together with the nitrogen atom to which they are attached, form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms independently selected from O and S and/or 1 or 2 groups independently selected from S(O), S(O)₂, NH and NCi.₄alkyl;

WO 2006/046039

PCT/GB2005/004144

Y is C=O or -CR^I4aR^15a-;

Z is a bond or NR¹⁰;

R¹⁰ is hydrogen, hydroxy, Chalky!, C2.6alkenyl, C2.6alkynyl, Ci.6alkoxy, C(O)Ci.6alkyl, Het, (CH2)o.3NR¹⁶R¹⁷, C(0)(CH2)o.₃NR¹⁶R¹⁷ and NHC(O)(CH₂)₀.₃NR¹⁶R¹⁷;

R¹⁴, R^14a, R¹⁵ and R^15a are each independently selected from hydrogen, hydroxy, Ci.6alkyl, C2.6alkenyl, C2.6alkynyl, (CH2)0.3C3.8cycloalkyl, Ci.6alkoxy, C(O)Ci.6alkyl, (CH2)o-3aryl, (CH2)0.3Het, C(O)(CH2)0-3Het, (CH2)o.3NR¹⁶R¹⁷, (CH2)₀.₃OR¹⁶, (CH2)0.3C(O)(CH2 )o.3NR^I6R¹⁷, NR¹⁸C(0)(CH2)o.₃NR¹⁶R¹⁷, S(0)o.2(CH2)0.3NR¹⁶R¹⁷, (CH2)₀.₃heteroaryl or C(O)(CH₂)₀.₃heteroaryl, optionally substituted by one or two groups independently selected from Ci.₆alkyl, hydroxy, halogen, Ci-galkoxy, SH and S(Ci.₆alkyl);

R¹⁶ and R¹⁷ are independently selected from hydrogen, Ci.6alkyl, (CH2)0.4NR^I8R¹⁹, (CH2)o-₃Het, (CH₂)o.₃heteroaryl, (CH2)o-₃C(0)(CH₂)o-₃NR¹⁸R¹⁹ or (CH₂)o-₃C₃.8cycloalkyl, optionally substituted by Chalky!, (CH₂)₀.₃OH or (CH₂)₀.₃C₁.₆alkoxy;

or R¹⁶ and R¹⁷, together with the nitrogen atom to which they are attached, form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O and S and/or 1 or 2 groups independently selected from S(O), S(O)₂, NH, NCi.₄alkyl and N(CH₂)o.₃Ci.₄alkoxy, and which ring is optionally substituted by halogen, hydroxy, C].₄alkyl or Ci.₄alkoxy;

R¹⁸ and R¹⁹ are independently selected from hydrogen, Ci.₆alkyl and heteroaryl;

or R¹⁸ and R¹⁹, together with the nitrogen atom to which they are attached, form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O and S and/or 1 or 2 groups selected from S(O), S(O)₂, NH and NC].₄alkyl, and which ring is optionally substituted by halogen, hydroxy, Ci.₄alkyl or Ci.₄alkoxy;

and pharmaceutically acceptable salts thereof;

with the proviso that the compound of formula (I) is not methyl 13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate, or 13-cyclohexyl-6,7-dihydro-5//-indolo[2,1-a] [2]benzazepine-10-carboxylic acid.

Another favoured group of compounds of the present invention is the compound of formula (la):

<img file="AU2005298412B2_D0008.tif" />

wherein

WO 2006/046039

PCT/GB2005/004144

Ar is a five- or six-membered aromatic ring optionally containing 1, 2 or 3 heteroatoms independently selected from N, O, and S;

Yis C=O or-CR^I4aR^15a;

Z is a bond or NR¹⁰;

R¹⁰, R¹⁴, R¹⁵, R^14a and R^15a are each independently selected from hydrogen, hydroxy, C,.6alkyl, C2.6alkenyl, C,.6alkoxy, C(O)C,.6alkyl, Het, (CH2 )0.3NR¹⁶R¹⁷, C(O)(CH2 )_o.₃NR¹⁶R¹⁷ and NHC(0)(CH₂)o.₃NR¹⁶R¹⁷;

R¹⁶ and R¹⁷ are independently selected from hydrogen, Chalky! and (CH₂)o.₄NR¹⁸R¹⁹;

or R¹⁶, R¹⁷ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O or S or a group S(O), S(O)₂, NH or NC ,.₄alkyl, and which ring is optionally substituted by halogen, hydroxy, C,.₄alkyl or C,.₄alkoxy;

R¹⁸ and R¹⁹ are independently selected from hydrogen and C,.₆alkyl;

or R¹⁸, R¹⁹ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring may optionally contain 1 or 2 more heteroatoms selected from O or S or a group S(O), S(O)₂, NH or NC,.₄alkyl, and which ring is optionally substituted by halogen, hydroxy, C,.₄alkyl or C,.₄alkoxy;

and pharmaceutically acceptable salts thereof;

with the proviso that the compound of formula (la) is not methyl 13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxyIate.

In one embodiment, Ar is a five- or six-membered aromatic ring optionally containing 1 or 2 heteroatoms independently selected from N, O and S. Preferably, Ar is a five- or six-membered aromatic ring optionally containing one heteroatom selected from N, O and S. More preferably, Ar is phenyl, pyridinyl, furyl or thienyl. Most preferably, Ar is phenyl or thienyl.

When Z is NR¹⁰, preferably R¹⁰ is hydrogen, C,.6alkyl or (CH2)o.3NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are as defined in relation to formula (la). More preferably, R¹⁰ is C,.6alkyl or (CH₂),.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are independently selected from hydrogen and C,.6alkyl. Most preferably, R¹⁰ is C,.4alkyl or (CH₂),.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are independently selected from hydrogen and C,.4alkyl. Examples of suitable R¹⁰ groups include methyl and (CH2)₂N(CH₃)₂.

In another embodiment, R¹⁴, R¹⁵, R^14a and R^15a are each independently selected from hydrogen, C,.6alkyl and (CH2)0.3NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are as defined in relation to formula (la). Preferably R¹⁴, R¹⁵, R^14a and R^15a are each independently selected from hydrogen and (CH2)₀.₃NR¹⁶R¹⁷, where R¹⁶and R¹⁷ are independently selected from hydrogen, C,.4alkyl and (CH2),.3NR¹⁸R¹⁹, where R¹⁸ and R¹⁹ are as defined in relation to formula (la). More preferably, R¹⁴, R¹⁵, R^14a and R^15a are each independently selected from hydrogen and NR¹⁶R¹⁷ where R¹⁶ and R¹⁷ are independently selected from hydrogen, methyl and (CH2),.₃NR¹⁸R¹⁹, where R¹⁸ and R¹⁹ are independently selected from hydrogen and C,.₄alkyl.

WO 2006/046039

PCT/GB2005/004144

Examples of suitable R¹⁴, R¹⁵, R^I4a and R^15a groups include hydrogen, NH(CH₂)2N(CH₃)2 and N(CH₃)(CH₂)2N(CH₃)2.

In another embodiment, Y is -CR^14aR^15a-. Preferably, Y is -CHR^14a-.

Another favoured group of compounds of the present invention is of formula (lb) and pharmaceutically acceptable salts thereof:

<img file="AU2005298412B2_D0009.tif" />

wherein

R¹⁰ is hydrogen, Ci.₆alkyl, C₂.6alkenyl, C₂.6alkynyl or (CH₂)i.₃NR¹⁶R¹⁷;

R¹⁶ and R¹⁷ are independently selected from hydrogen and Ci^alkyl;

R^14a and R^15a are independently selected from hydrogen, Ci.₆alkyl, C^alkenyl, C^alkynyl or C₃.gcycloalkyl;

or R^I4a and R^15a together form an oxo group;

with the proviso that the compound of formula (lb) is not

3-chloro-14-cyclohexyl-5-(2-piperidin-l-ylethyl)-5,6,7,8-tetrahydroindolo[l,2-&lt;?][l,5]benzodiazocine-llcarboxylic acid.

In one embodiment, R¹⁰ is hydrogen, Ci.6alkyl or (CH2)i.3NR¹⁶R¹⁷, where R¹⁶ and R¹⁷are as defined in relation to formula (lb). Preferably, R¹⁰ is Ci.6alkyl or (CH₂)i.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are independently selected from hydrogen and CMalkyl. More preferably, R¹⁰ is Ci.4alkyl or (CH₂)2N(Ci.₄alkyl)2. Examples of suitable R¹⁰ groups include methyl and (CH₂)N(CH₃)₂.

In another embodiment, R^14a and R^15a are independently selected from hydrogen or Cj^alkyl, or R^14a and R^1Sa together form an oxo group. Preferably, R^14a and R^15a are independently selected from hydrogen or Chalky!, or R^14a and R^15a together form an oxo group. More preferably, R^14a and R^15a are both hydrogen, or R^14a and R^15a together form an oxo group.

Another favoured group of compounds of the present invention is of formula (Ic) and pharmaceutically acceptable salts thereof:

WO 2006/046039

PCT/GB2005/004144 wherein

R¹⁰ is hydrogen, Ci.₆alkyl, C₂.₆alkenyl or C₂.6alkynyl;

R¹⁴ and R¹⁵ are independently selected from hydrogen, Ci.₆alkyl, C₂.₆alkenyl, C₂.₆alkynyl or (CH₂)_o.₃NR¹⁶R¹⁷; and

R¹⁶ and R¹⁷ are independently selected from hydrogen and Ci.₆alkyl.

In one embodiment, R¹⁰ is hydrogen or C^alkyl. Preferably, R¹⁰ is hydrogen or C_Malkyl. More preferably, R¹⁰ is methyl.

In another embodiment, R¹⁴and R¹⁵are independently selected from hydrogen, C].6alkyl or (CH2)o.3NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are independently selected from hydrogen and CMalkyl. Preferably, R¹⁴and R¹⁵ are independently selected from hydrogen, Ci.4alkyl or NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are independently selected from hydrogen and methyl. More preferably, R¹⁴ and R^1S are hydrogen or N(CH3)₂.

Another favoured group of compounds of the present invention is of formula (Id) and pharmaceutically acceptable salts thereof:

wherein

Ar is a five- or six-membered aromatic ring optionally containing 1, 2 or 3 heteroatoms independently selected from N, O and S, which ring is optionally substituted by group Q¹;

R¹⁴, R¹⁵, R^14a, R^15a and Q¹ are as defined in relation to formula (I), with the proviso that the compound of formula (Id) is not methyl 13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate, or

13-cyclohexyl-6,7-dihydro-5H-pyrrolo[2',Γ:3,4][ 1,4]diazepino[ 1,2-a]indole-10-carboxylic acid.

WO 2006/046039

PCT/GB2005/004144

In one embodiment, Ar is a five- or six-membered aromatic ring optionally containing 1 or 2 heteroatoms independently selected from N, O and S, which ring is optionally substituted by halogen, hydroxy, C^alkyl or Cbsalkoxy. Preferably, Ar is a five- or six-membered aromatic ring optionally containing one heteroatom selected from N, O and S, which ring is optionally substituted by halogen, hydroxy or Ci.₄alkoxy. More preferably, Ar is a five- or six-membered aromatic ring optionally containing one S atom, which ring is optionally substituted by C₁.₄alkoxy. More preferably, Ar is phenyl or thienyl, optionally substituted by methoxy.

In another embodiment, R¹⁴, R¹⁵, R^,4a and R^15a are independently selected from hydrogen, Ci.6alkyl, (CH2)0.3OR¹⁶ and (CH2)o.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are as defined in relation to formula (Id). Preferably, one of R¹⁴ and R^,4ais hydrogen, Ci.6alkyl, (CH2)0.3OR¹⁶ or (CH2)₀.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷are as defined in relation to formula (I), and the other of R¹⁴and R^14a is hydrogen. More preferably, one of R¹⁴ and R^14a is (CH2)0.3OR¹⁶ or (CH2)₀.₃NR¹⁶R¹⁷, where R¹⁶ and R¹⁷ are as defined in relation to formula (Id), and the other of R¹⁴ and R^I4a is hydrogen. Most preferably, one of R¹⁴ and R^14a is OR¹⁶ or NR¹⁶R¹⁷, where R¹⁶ and R¹⁷are as defined in relation to formula (I), and the other of R¹⁴ and R^14a is hydrogen.

When any one or more of R¹⁴, R¹⁵, R^14a and R^15a is (CHADOR¹⁶ or (CH2)0.3NR¹⁶R¹⁷, preferably R¹⁶ and R¹⁷ are independently selected from hydrogen, Cb6alkyl, (CH₂)₀.₄NR¹⁸R¹⁹, (CH2)0.3Het, (CH2)0.3heteroaryl, (CH2)0.3C(O)(CH2 )0.3NR¹⁸R¹⁹ or (CH2)o.₃C₃.₈cycloalkyl, where R¹⁸ and R¹⁹ are as defined in relation to formula (I). More preferably, R¹⁶ and R¹⁷ are independently selected from hydrogen, Ci^alkyl and (CH2)!.3NR¹⁸R¹⁹, where R¹⁸ and R¹⁹ are as defined in relation to formula (I). Most preferably, R¹⁶ and R¹⁷ are independently selected from hydrogen, Ci.4alkyl and (CH₂)i.₃NR¹⁸R¹⁹, where R¹⁸ and R¹⁹ are independently selected from hydrogen and Ci.6alkyl, or R¹⁸ and R¹⁹ together with the nitrogen atom to which they are attached, form a heteroaliphatic ring of 5 or 6 ring atoms, which ring may optionally contain 1 more O or S atom and/or a NH or NCi.4alkyl group. Especially, R¹⁶ and R¹⁷ are independently selected from hydrogen, methyl and (CH₂)₂NR¹⁸R¹⁹, where R¹⁸ and R¹⁹ are independently selected from methyl and ethyl, or R¹⁸ and R¹⁹, together with the nitrogen atom to which they are attached form a pyrrolidinyl ring. Examples of suitable R¹⁴, R¹⁵, R^14a and R^15a groups include hydrogen,

<img file="AU2005298412B2_D0010.tif" />

WO 2006/046039

PCT/GB2005/004144

Preferably, R¹⁵ and R^15a are independently selected from hydrogen and Ci^alkyl. More preferably, R¹⁵and R^15aare independently selected from hydrogen and Ci.₄alkyl. Most preferably, R¹⁵ and R^15a are independently selected from hydrogen, methyl and ethyl. Especially, R¹⁵ and R^I5a are both hydrogen.

When any variable occurs more than one time in formula (I) or in any substituent, its definition on each occurrence is independent of its definition at every other occurrence.

As used herein, the term “alkyl” or “alkoxy” as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.

The cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. A suitable cycloalkylalkyl group may be, for example, cyclopropylmethyl.

As used herein, the term “alkenyl” as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl.

When used herein, the term “halogen” means fluorine, chlorine, bromine and iodine.

When used herein, the term “aryl” as a group or part of a group means a carbocyclic aromatic ring. Examples of suitable aryl groups include phenyl and naphthyl.

When used herein, the term “heteroaryl” as a group or part of a group means a 5- to 10-membered heteroaromatic ring system containing 1 to 4 heteroatoms selected from N, O and S. Particular examples of such groups include pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indolyl, benzothienyl, benzimidazolyl and quinolinyl.

When used herein, the term “Het” as a group or part of a group means a heteroaliphatic ring of 4 to 7 atoms, which ring may contain 1, 2 or 3 heteroatoms selected from N, O and S or a group S(O), S(O)₂, NH or NC_Malkyl.

Where a compound or group is described as “optionally substituted” one or more substituents may be present. Optional substituents may be attached to the compounds or groups which they substitute in a variety of ways, either directly or through a connecting group of which the following are examples: amine, amide, ester, ether, thioether, sulfonamide, sulfamide, sulfoxide, urea, thiourea and urethane. As appropriate an optional substituent may itself be substituted by another substituent, the latter being connected directly to the former or through a connecting group such as those exemplified above.

Specific compounds within the scope of this invention include those named in the Examples and Tables below and their pharmaceutically acceptable salts.

For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a

WO 2006/046039

PCT/GB2005/004144 pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulfuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the parent drug or parent molecule) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulfate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.

The present invention also includes within its scope N-oxides of the compounds of formula (I).

The present invention also includes within its scope any enantiomers, diastereomers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.

The present invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in therapy.

In another aspect, the invention provides the use of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treatment or prevention of infection by hepatitis C virus in a human or animal.

A further aspect of the invention provides a pharmaceutical composition comprising a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. The composition may be in any suitable form, depending on the

WO 2006/046039

PCT/GB2005/004144 intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally.

The pharmaceutical compositions optionally also include one or more other agents for the treatment of viral infections such as an antiviral agent, or an immunomodulatory agent such as α-, β- or γ interferon.

In a further aspect, the invention provides a method of inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal (preferably mammalian) subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical composition described above or of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof. “Effective amount” means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject’s condition.

The dosage rate at which the compound is administered will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition and the host undergoing therapy. Suitable dosage levels may be of the order of 0.02 to 5 or 10 g per day, with oral dosages two to five times higher. For instance, administration of from 10 to 50 mg of the compound per kg of body weight from one to three times per day may be in order. Appropriate values are selectable by routine testing. The compound may be administered alone or in combination with other treatments, either simultaneously or sequentially. For instance, it may be administered in combination with effective amounts of antiviral agents, immunomodulators, anti-infectives or vaccines known to those of ordinary skill in the art. It may be administered by any suitable route, including orally, intravenously, cutaneously and subcutaneously. It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell. Suitable targeting methods are already known.

An additional aspect of the invention provides a method of preparation of a pharmaceutical composition, involving admixing at least one compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable adjuvants, diluents or earners and/or with one or more other therapeutically or prophylactically active agents.

The present invention also provides a process for the preparation of compounds of formula (I).

According to a general process (a), compounds of formula (I) may be prepared by internal ring closure of a compound of formula (II):

<img file="AU2005298412B2_D0011.tif" />

A

WO 2006/046039

PCT/GB2005/004144 wherein R¹, R², A and Ar are as defined in relation to formula (I) and X’ is converted to -CR¹⁴R¹⁵- during or after the cyclisation reaction, W’ is -CH₂- or is converted to -CH₂- during or after the cyclisation reaction, Y’ is converted to Y during or after the cyclisation reaction, and Z’ is Z or is converted to Z during or after the cyclisation reaction. W’, X’, Y’ and Z’ may be suitable activated precursors of groups -CH₂-, X, Y and Z respectively which can be converted into -CH₂-, X, Y and Z during the ring closure or after it using methods described in the accompanying Schemes and Examples or known to the person skilled in the art. For example, when Z is a bond, W’, X’, Y’ and Z’ are suitable precursors which are olefinic or can be converted to olefins in order to undergo a ring-closure methathesis reaction.

Alternatively, when Z is NR¹⁰, X’ may be CH₂-halogen, CH₂-ester, CH₂-aldehyde, an epoxide or an aziridine group.

According to a general process (b), compounds of formula (I) may be prepared by internal ring closure of a compound of formula (III):

W'-^X' Y\

<img file="AU2005298412B2_D0012.tif" />

A wherein R¹, R², A, Ar, Y and Z are as defined in relation to formula (I) and X’ is -CR¹⁴R¹⁵- or is converted to -CR^I4R¹⁵- during or after the cyclisation reaction, and W’ is converted to -CH2- during or after the cyclisation reaction. W’ and X’ may be suitable activated precursors of groups -CH2- and -CR¹⁴R¹⁵- respectively which can be converted into -CH2-and -CR¹⁴R¹⁵- during the ring closure or after it using methods described in the accompanying Schemes and Examples or known to the person skilled in the art. For example, W’ may be CH₂-halogen or W’ and X’ together may be an epoxide or aziridine group. When W’ is CH₂-halogen, such as CH₂-Br, the reaction is conveniently performed in the presence of a base, such as sodium hydroxide, in a suitable solvent, such as DMF. When W’ and X’ are an epoxide group, the reaction is conveniently performed in the presence of a base, such as sodium hydroxide, in a suitable solvent, such as DMF.

Compounds of formulae (II) and (III) are either known in the art or may be prepared by conventional methodology well known to one of ordinary skill in the art using, for instance, procedures described in the accompanying Schemes and Examples, or by alternative procedures which will be readily apparent.

Further details of suitable procedures will be found in the accompanying Schemes and Examples. For instance, compounds of formula (I) can be converted into other compounds of formula (I) using synthetic methodology well known in the art.

WO 2006/046039

PCT/GB2005/004144

General Synthetic schemes

In general, five synthetic schemes may be used to obtain the compounds of formula (I).

Method A

<img file="AU2005298412B2_D0013.tif" />

1) Functional group manipulation

<img file="AU2005298412B2_D0014.tif" />

2-bromoindole intermediate (prepared as described in published International patent application W02004/087714) was functionalized on the indole nitrogen to introduce precursor functionality W’/X’ to either or both of the elements -CH₂-/X of the tether. Pd-mediated cross-coupling methodology (eg, Suzuki, Stille etc) then brought in the C2 aromatic bearing pre-cursor functionality ΖΊΥ' to either or both of the elements Z/Y of the tether. Functional group manipulation followed by ring closure afforded the tetracyclic system. Ester deprotection then yielded the target indole carboxylic acids, with the C2 aromatic tethered to the indole nitrogen.

Method B

<img file="AU2005298412B2_D0015.tif" />

<img file="AU2005298412B2_D0016.tif" />

1) Functional group manipulation

<img file="AU2005298412B2_D0017.tif" />

2) tether assembly

<img file="AU2005298412B2_D0018.tif" />

WO 2006/046039

PCT/GB2005/004144

The C2 aromatic was introduced at the outset via Pd-mediated cross-coupling methodology (Suzuki, Stille etc). The tether was then built up, with cyclisation onto the indole nitrogen finally closing the ring. Ester deprotection then yielded the target indole carboxylic acids, with the C2 aromatic tethered to the indole nitrogen.

Method C

<img file="AU2005298412B2_D0019.tif" />

1) functional group manipulation

<img file="AU2005298412B2_D0020.tif" />

2) deprotection

Fused tetracyclic intermediates arising from Methods A and B underwent manipulation of the functionality in the tether prior to ester deprotection to yield the target C2-tethered indole carboxylic acids.

<img file="AU2005298412B2_D0021.tif" />

carboxylate manipulation

------►

<img file="AU2005298412B2_D0022.tif" />

C2-tethered indole carboxylic acids arising from Methods A-C were further derivatised through manipulation of the carboxylate functionality to give compounds bearing a carboxylate replacement or carboxamide.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene &amp; P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley &amp; Sons, 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples are illustrative of this invention.

The compounds of the invention were tested for inhibitory activity against the HCV RNA dependent

RNA polymerase (NS5B) in an enzyme inhibition assay (example i)) and in a cell based sub-genomic

WO 2006/046039

PCT/GB2005/004144 replication assay (example ii)). The compounds have IC50’s below 5 μΜ in the enzyme assay and several examples have EC50’s below 2 μΜ in the cell based assay.

Compound names in the examples were generated using software from ACDLabs (version 6.0).

i) In-vitro HCV NS5B Enzyme Inhibition Assay

WO 96/37619 describes the production of recombinant HCV RdRp from insect cells infected with recombinant baculovirus encoding the enzyme. The purified enzyme was shown to possess in vitro RNA polymerase activity using RNA as template. The reference describes a polymerisation assay using poly(A) and oligo(U) as a primer or an heteropolymeric template. Incorporation of tritiated UTP or NTPs is quantified by measuring acid-insoluble radioactivity. This assay has been employed to screen the various compounds described above as inhibitors of HCV RdRp.

Incorporation of radioactive UMP was measured as follows. The standard reaction (50 μΐ) was carried out in a buffer containing 20 mM tris/HCI pH 7.5, 5 mM MgCl₂, 1 mM DTT, 50 mM NaCl, 0.03% N-octylglucoside, 1 pCi [³H]-UTP (40 Ci/mmol, NEN), 10 μΜ UTP and 10 μ§/ιη1 poly(A) or 5μΜ NTPs and 5μg/ml heteropolymeric template. Oligo(U)i2 (1 μg/ml, Genset) was added as a primer in the assay working on Poly(A) template. The final NS5B enzyme concentration was 5 nM. The order of assembly was: 1) compound, 2) enzyme, 3) template/primer, 4) NTP. After 1 h incubation at 22 °C the reaction was stopped by adding 50 μΐ of 20% TCA and applying samples to DE81 filters. The filters were washed thoroughly with 5% TCA containing IM Na2HPO4/NaH₂PO4, pH 7.0, rinsed with water and then ethanol, air dried, and the filter-bound radioactivity was measured in the scintillation counter. Carrying out this reaction in the presence of various concentrations of each compound set out above allowed determination of IC50 values by utilising the formula:

% Residual activity = 100/(l+[I]/IC₅₀)^s where [I] is the inhibitor concentration and “s” is the slope of the inhibition curve.

ii) Cell based HCV Replication Assay

Cell clones that stably maintain subgenomic HCV replicon were obtained by transfecting Huh-7 cells with an RNA replicon identical to l377neo/NS3-3’/wt described by Lohmann et al. (1999) (EMBLgenbank No. AJ242652), followed by selection with neomycin sulfate (G418). Viral replication was monitored by measuring the expression of the NS3 protein by an ELISA assay performed directly on cells grown in 96 wells microtiter plates (Cell-ELISA) using the anti-NS3 monoclonal antibody 10E5/24 (as described in published International patent application WO02/59321). Cells were seeded into 96 well plates at a density of 10⁴ cells per well in a final volume of 0.1 ml of DMEM/10% FCS. Two hours after plating, 50 μΐ of DMEM/10% FCS containing a 3x concentration of inhibitor were added, cells were incubated for 96 hours and then fixed for 10' with ice-cold isopropanol. Each condition was tested in

WO 2006/046039

PCT/GB2005/004144 duplicate and average absorbance values were used for calculations. The cells were washed twice with PBS, blocked with 5% non-fat dry milk in PBS + 0.1% Triton X100 + 0.02% SDS (PBSTS) and then incubated o/n at 4°C with the 10E5/24 mab diluted in Milk/PBSTS. After washing 5 times with PBSTS, the cells were incubated for 3 hours at room temperature with Fc specific anti-mouse IgG conjugated to alkaline phosphatase (Sigma), diluted in Milk/PBSTS. After washing again as above, the reaction was developed with p-Nitrophenyl phosphate disodium substrate (Sigma) and the absorbance at 405/620 nm read at intervals. For calculations, we used data sets where samples incubated without inhibitors had absorbance values comprised between 1 and 1.5. The inhibitor concentration that reduced by 50% the expression of NS3 (IC₅₀) was calculated by fitting the data to the Hill equation,

Fraction inhibition = l-(Ai-b)/(Ao-b) = [I]ⁿ / ([I]ⁿ + IC₅₀) where:

- Ai = absorbance value of HBI10 cells supplemented with the indicated inhibitor concentration.

- Ao = absorbance value of HBI10 cells incubated without inhibitor.

- b = absorbance value of Huh-7 cells plated at the same density in the same microtiter plates and incubated without inhibitor.

- n = Hill coefficient.

iii) General Procedures

All solvents were obtained from commercial sources (Fluka, puriss.) and were used without further purification. With the exception of routine deprotection and coupling steps, reactions were carried out under an atmosphere of nitrogen in oven dried (110 °C) glassware. Organic extracts were dried over sodium sulfate, and were concentrated (after filtration of the drying agent) on rotary evaporators operating under reduced pressure. Flash chromatography was carried out on silica gel following published procedure (W.C. Still et al., J. Org. Chem. 1978,43, 2923) or on commercial flash chromatography systems (Biotage corporation and Jones Flashmaster Π) utilising pre-packed columns.

Reagents were usually obtained directly from commercial suppliers (and used as supplied) but a limited number of compounds from in-house corporate collections were utilised. In the latter case the reagents are readily accessible using routine synthetic steps that are either reported in the scientific literature or are known to those skilled in the art.

*H NMR spectra were recorded on Bruker AM series spectrometers operating at (reported) frequencies between 300 and 600 MHz. Chemical shifts (δ) for signals corresponding to nonexchangeable protons (and exchangeable protons where visible) are recorded in parts per million (ppm) relative to tetramethylsilane and are measured using the residual solvent peak as reference. Signals are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad, and combinations thereof); coupling constant(s) in hertz (Hz); number of protons. Mass spectral (MS) data were obtained on a Perkin Elmer API 100, or Waters MicroMass ZQ, operating in negative (ES') or positive (ES⁺) ionization mode and results are reported as the ratio of mass over charge (m/z) for the

WO 2006/046039

PCT/GB2005/004144 parent ion only. Preparative scale HPLC separations were carried out on a Waters Delta Prep 4000 separation module, equipped with a Waters 486 absorption detector or on a Gilson preparative system. In all cases compounds were eluted with linear gradients of water and MeCN both containing 0.1% TFA using flow rates between 15 and 40 mL/min.

The following abbreviations are used in the examples, the schemes and the tables:

Ac: acetyl; Ar: aryl; cat.: catalytic; dioxan(e): 1,4-dioxane; dppf: (l,l'-bisdiphenylphosphmo)ferrocene; 1,2-DCE: 1,2-dichloroethane; DCM: dichloromethane; DIPEA: diisopropylethyl amine; DMAP: N,Ndimethylpyridin-4-amine; DME: dimethoxyethane; DMF: dimethylformamide; DMSO: dimethylsulfoxide; DMP: Dess-Martin Periodinane; EDAC.HC1: l-ethyl-(3dimethylaminopropyl)carbodiimide HC1 salt; eq.: equivalent(s); Et₃N: triethylamine; EtOAc: ethyl acetate; Et₂O: diethyl ether; EtOH: ethanol; h: hour(s); Et₃SiH: triethylsilane; HOAc: acetic acid; HATU: 0-(7-azabenzotriazol-l-yl)-/V,/V,/V’,A/’-tetramethyluronium hexafluorophophate; Me: methyl; MeCN: acetonitrile; MeOH: methanol; min: minutes; MS: mass spectrum; NBS: /V-bromo succinimide; PE: petroleum ether; Ph: phenyl; quant.: quantitative; RP-HPLC: reversed phase high-pressure liquid chromatography; RT: room temperature; sec: second(s); SFC: Super-critical fluid chromatography; s.s.: saturated solution; TBTU: O-benzotriazol-l-yl-N,N,Ν',N'-tetramethyluronium tetrafluoroborate; TFA: trifluoroacetic acid; THF: tetrahydrofuran; THF: terhahydropyranyl; TMS: trimethylsilyl.

Reagents: Zhan catalyst I ([l,3-bis(2,4,6-trimethylphenyl)-4,5-dihydro-imidazol-2-ylidene]-[4-chloro-lisopropxy-benzylidine]ruthenium-dichloride: commercially available from ZannanPharma Ltd.

(www.zannanpharma.comy, methyl (aminosulfonyl)acetate was prepared in analogous fashion to related esters of aminosulfonyl acetic acid: eg, Tetrahedron Lett. 1989, 30 (22), 2869; Bull. Soc. Chim. France 1975, 3, 807.

Example 1: Preparation of 13-cyclohexyl-5-(2-pyrrolidin-l-ylethoxy)-6,7-dihydro-5H-indolo[2,la][2]benzazepine-10&gt;carboxylic acid and 13-cyclohexyl-6-(2-pyrrolidin-l-ylethoxy)-6,7-dihydro-5/7indolo[2,l-a][2]benzazepine-10-carboxylic acid

Step 1: Methyl 3-cyclohexvl-2-(2-vinylphenyl)-lH-indole-6-carboxvlate

Methyl 2-bromo-3-cyclohexyl-l//-indole-6-carboxylate (prepared as described in WO 2004/087714) and (2-vinylphenyl)boronic acid (1.5 eq) were dissolved in dioxane (0.07 M) and 2M aqueous Na₂CO₃ (6 eq) was added. The solution was degassed by bubbling argon, Pd(PPh₃)₂Cl₂ (0.2 eq) was added, and the reaction mixture was refluxed for 1 h; after cooling, EtOAc was added, and the solution washed with water and brine, dried over Na₂SO₄ and concentrated in vacuo. The title compound was isolated by chromatography (ΡΕ/EtOAc 9:1) in 91% yield; MS (ES⁺) m/z 360 (M+H)⁺.

WO 2006/046039

PCT/GB2005/004144

Step 2: methyl l-allyl-3-cyclohexyl-2-(2-vinylphenyl)-JH-indole-6-carboxylate

To a 0.3M solution of methyl 3-cyclohexyl-2-(2-vinylphenyl)-lH-indole-6-carboxylate in dry DMF, 60% NaH (1.5 eq) in mineral oil was added at 0 °C, after 1 h allyl bromide (1.5 eq) was added and the suspension was stirred at RT for 2 h. The mixture was diluted with EtOAc, washed with IN HC1, water and brine, dried over Na₂SO₄ and concentrated in vacuo to give the title compound (100% as crude); MS (ES⁺) m/z 400 (M+H)⁺.

Step 3: Methyl 13-cyclohexyl-7H-indolo[2.1-al[2lbenzazepine-10-carboxylate

Crude methyl l-allyl-3-cyclohexyl-2-(2-vinylphenyl)-lH-indole-6-carboxylate was dissolved in DCM (0.02M) and treated with Zhan catalyst I (0.3 eq) at 35 °C for 1 h. NEt₃ (7 eq) were added and the solvent was removed in vacuo. The residue was purified by chromatography (PE/EtOAc 95:5) to afford the title compound (84%); MS (ES*) m/z 372 (M+H)⁺.

Step 4: 13-cyclohexyl-5-(2-pyrrolidin-l-vlethoxy)-6,7-dihvdro-5H-indolo[2,l-a][2}benzazepine-10carboxylic acid and 13-cvclohexyl-6-(2-pyrrolidin-l-ylethoxy)-6.7-dihvdro-5H-indolo[2,la][2]benzazepine-10-carboxylic acid

BH₃ Me₂S (1.6 eq, 2M solution in THF) was added to a 0.2M solution of methyl 13-cyclohexyl-7Hindolo[2,l-a][2]benzazepine-10-catboxylate in THF, and the mixture was stirred for 2h at RT; 3M aq NaOH (3 eq) and 35% H₂O₂ (3 eq) were added at 0 °C, and stirring was continued overnight at RT. After dilution with saturated aqueous NaHCO₃ the aq. phase was extracted with EtOAc, the organic phase was washed with water and brine, dried over Na₂SO₄ and concentrated in vacuo to give a 4:1 mixture of methyl 13-cyclohexyl-5-hydroxy-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate and methyl 13-cyclohexyl-6-hydroxy-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate.

The foregoing crude was dissolved in toluene (20 ml/mmol), 40% aq NaOH (15 eq) and tetrabutyl ammonium bromide (0.25eq) were added, and the mixture was stirred for 30 min. 1-(2chloroethyl)pyrrolidine hydrochloride (3 eq) was then added and the resulting mixture heated at 70 °C for 1 day; evaporation to dryness gave a residue from which the two regioisomers were separated by RPHPLC (combined overall yield 32%) (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 mm; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

13-Cyclohexyl-5-(2-pyrrolidin-1 -ylethoxy)-6,7 -dihydro-5H-indolo[2,1 -a] [2]benzazepine- 10-carboxylic acid (major): Ή NMR (400 MHz, DMSO, 300 K) δ 1.16-1.51 (4H, m), 1.58-2.06 (12H, m), 2.82-2.90 (2H, m), 3.00-3.21 (3H, m), 3.45-3.75 (5H, m), 4.23-4.73 (2H, m), 7.46-7.64 (5H, m), 7.83-7.87 (1H, m), 8.13 (1H, s), 12.30 (1H, bs); MS (ES⁺) m/z 473 (M+H)⁺.

13-Cyclohexyl-6-(2-pyrrolidin-l-ylethoxy)-6,7-dihydro-5H-indolo[2,l-iz][2]benzazepine-10-carboxylic acid (minor): Ή NMR (400 MHz, DMSO, 330 K) δ 1.16-1.56 (4H, m), 1.68-2.26 (12H, m), 2.80-2.93 (1H, m), 2.98-3.18 (3H, m), 3.46-3.68 (4H, m), 3.78-3.83 (1H, m), 4.04-4.07 (1H, m), 4.18-4.37 (1H, m),

WO 2006/046039

PCT/GB2005/004144

4.75-4.90 (1H, m), 7.43-7.49 (4H, m), 7.65 (1H, dd, J 8.6, 1.1), 7.88 (1H, d, J 8.6), 8.13-8.22 (1H, m), 11.44 (1H, bs); MS (ES⁺) m/z 473 (M+H)⁺.

Example 2: Preparation of 13-cyclohexyl-5-[[2-(dimethylamino)ethyl]-(methyl)amino]-6,7-dihydro5//-iiidolo[2,l-«][2]benzazepine-10-carboxyIic acid

PBr₃ (0.5 eq) was added at 0 °C to a 0.2M solution of a mixture of the two regioisomers methyl 13cyclohexyl-5-hydroxy-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate and methyl 13cyclohexyl-6-hydroxy-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate (prepared as described in Example 1, Step 4) in DCM, and the mixture was stirred at RT for 2h. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over Na₂SO₄ and concentrated in vacuo to give the mixture of methyl 5-bromo-13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10carboxylate and methyl 6-bromo-13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10carboxylate that was dissolved in MeCN and treated with /V,/V,V-trimethylethane-l,2-diamine (8 eq) at 55 °C for 3 h; evaporation in vacuo to dryness gave crude methyl 13-cyclohexyI-5-[methyl(2-pyrrolidin-lylethyl)amino]-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate together with the unreacted methyl 6-bromo-13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10-carboxylate. Hydrolysis of the foregoing mixture of methyl esters was done with IM aqueous KOH (6 eq) in dioxane (0.1M) at 60 °C; the reaction was complete in 2 h, and the title compound was obtained in 49% yield after RP-HPLC purification and lyophilisation (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 mm; flow: 20 ml/min; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

'H NMR (400 MHz, DMSO, 300 K) 8 1.15-1.78 (6H, m), 1.82-2.09 (5H, m), 2.19-2.30 (3H, m), 2.55-2.7 (2H, m), 2.78 (6H, s), 2.80-2.96 (1H, m), 3.13-3.40 (4H, m), 4.60-4.66 (1H, m), 7.40 (1H, d, JI.2), 7.477.56 (2H, m), 7.62 (1H, d, 78.3), 7.75 (1H, d, 77.2), 7.87 (1H, d, 78.3), 8.14 (1H, s); MS (ES⁺) m/z 460 (M+H)⁺.

Example 3: Preparation of 13-cycIohexyl-5-[(2-pyrrolidin-l-ylethyl)amino]-6,7-dihydro-5Hindolo[2,l-a][2]benzazepine-10-carboxylic acid

A 0.03M solution of 5-bromo-13-cyclohexyl-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine-10carboxylate (prepared as in Example 2) in MeCN was treated with (2-pyrrolidin-l-ylethyl)amine (5 eq) at 55 °C for 4 h; evaporation in vacuo to dryness gave crude methyl 13-cyclohexyl-5-[(2-pyrrolidin-lylethyl)amino]-6,7-dihydro-5/7-indolo[2,l-a][2]benzazepine-10-carboxylate. Hydrolysis of the foregoing methyl ester was done with IM aqueous KOH (6 eq) in dioxane (0.1M) at 60 °C; the reaction was complete in 2 h, and the title compound was obtained in 24% yield after RP-HPLC purification and lyophilisation (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 nun; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

WO 2006/046039

PCT/GB2005/004144 *H NMR (400 MHz, DMSO, 300 K) δ 1.15-1.77 (7H, m), 1.90-2.17 (10H, m), 2.78-2.91 (2H, m), 3.403.59 (7H, m), 4.11-4.16 (1H, m), 4.75-4.81 (1H, m), 7.51-7.66 (5H, m), 7.92 (1H, d, J 8.5), 8.20 (1H, s); MS (ES⁺) m/z 472 (M+H)⁺.

Example 4: Preparation of 13-cyclohexyl-5-[methyl(2-pyrrolidin-l-ylethyl)amino]-6,7-dihydro-5//indolo[2,l-a][2]benzazepine-10-carboxylic acid

Methyl 13-cyclohexyl-5-[(2-pyrrolidin-l-ylethyl)amino]-6,7-dihydro-5//-indolo[2,l-a] [2]benzazepine10-carboxylate (prepared as in Example 3) was dissolved in DCM and the pH adjusted to 6 with AcOH; 37% aq HCHO and, after 30 min NaCNBH₃ (3 eq), were added and the mixture was stirred at RT overnight. The reaction mixture was diluted with EtOAc and washed with IN NaOH and brine, dried and evaporated affording methyl 13 -cyclohexyl-5 -[methyl(2-pyrrolidin-1 -ylethyl)amino] -6,7-dihydro-5//indolo[2,l-a][2]benzazepine-10-carboxylate. Hydrolysis of the foregoing methyl ester was done with IM aqueous KOH (6 eq) in dioxane (0.1M) at 60 °C; the reaction was complete in 2 h, and the title compound was obtained in 29% yield after RP-HPLC purification and lyophilisation (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 mm; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

Ή NMR (400 MHz, DMSO, 300 K) δ 1.16-1.77 (8H, m), 1.80-2.11 (8H, m), 2.19-2.31 (2H, m), 2.612.87 (5H, m), 2.98-3.41 (7H, m), 4.54-4.66 (1H, m), 7.42 (1H, d, J 8.1), 7.47-7.54 (2H, m), 7.63 (1H, d, J 8.3), 7.69-7.75 (1H, m), 7.86 (1H, d, J 8.3), 8.12 (1H, s); MS (ES⁴) m/z 486 (M+H)⁺.

Example 5: Preparation of 13-cyclohexyl-6-{[2-(dimethylamino)ethyl]amino}-6,7-dihydro-5Z/indolo[2,l-a][2]benzazepine-10-carboxylic acid

Step 1: Methyl 13-cyclohexvl-5,6-dihydroxy-6.7-dihydro-5H-indole[2.1 -aU2lbenzazepine-10-carboxvlate A solution (0.11 M) of methyl 13-cyclohexyl-7H-indolo[2,l-a][2]benzazepine-10-carboxylate (prepared as in Example 1, Step 3) in acetone/THF/H₂O (1/1/1) was treated with V-methylmorpholineW-oxide (1.2 eq), followed by OsO₄ (4% wt in H₂O) (0.1 eq) and left stirring at RT overnight. The clear solution was then treated with 10% wt Na₂SO₃ and left stirring for 30 min, then diluted with H₂O and extracted with EtOAc. The organic phase was washed with brine, dried over Na₂SO₄ and evaporated in vacuo to give the clean title compound as a creamy solid; MS (ES⁺) m/z 406 (M+H)⁺.

Step 2: Methyl 10-cyclohexyl-2-oxo-3a.l4b-dihydro-4H-i 1,3ldioxolo[4,5-dlindolo[2,l -al f 2 lbenzazepine-7-carboxylate

A solution (0.05 M) of methyl 13-cyclohexyl-5,6-dihydroxy-6,7-dihydro-5H-indole[2,l-a][2] benzazepine-10-carboxylate in DCM was treated with Et₃N(4 eq), and cooled to -50 °C. Triphosgene (0.4 eq) was added and the solution allowed to warm to RT over 30 min. After 2 h at RT, satd. NaHCO₃

WO 2006/046039

PCT/GB2005/004144 was added and the solution extracted with EtOAc. The organic phase was washed with H₂O, brine, dried (Na₂SO₄) and evaporated in vacuo to leave the clean title compound; MS (ES⁺) m/z 432.3 (M+H)⁺.

Step 3: Methyl 13-cyclohexyl-6-hydroxy-6,7-dihydro-5H-indolo[2.1-a] [21benzazepine-10-carboxylate A solution (0.02 M) of methyl 10-cyclohexyl-2-oxo-3a,14b-dihydro-4H-[l,3]dioxolo[4,5-d]indolo[2,la][2]benzazepine-7-carboxylate in acetone/MeOH (3/1) was treated with Raney-Ni (slurry in water) and the vigorously stirred reaction mixture was hydrogenated at 1 atm H₂. After 48 h the solid was filtered and the filtrates evaporated in vacuo to leave the clean title compound; MS (ES⁺) m/z 390.3 (M+H)⁺.

Step 4: 13 -cyclohexyl-6- ([2-(dimethy lamino)ethyl] amino )-6,7 -dihydro-5H-indolol2,1 -al [21benzazepine10-carboxylic acid

A solution (0.05 M) of methyl 13-cyclohexyl-6-hydroxy-6,7-dihydro-5H-indolo[2,l-a] [2]benzazepine10-carboxylate in DCM was treated with DMP (1.3 eq) at 0 °C and left warming to RT and then stirred for 2 h under nitrogen. The solution was then diluted with EtOAc and washed with satd. NaHCO₃, water, brine, dried over Na₂SO₄ and evaporated in vacuo to afford methyl 13-cyclohexyl-6-oxo-6,7-dihydro-5Hindolo[2,l-a][2] benzazepine-10-carboxylate. The crude material was dissolved in 1,2-DCE (0.05 M), 2dimethylamino-ethylamine was added and the pH adjusted to 6 with AcOH and the solution left storing for 30 min. NaBH(OAc)₃ was added and the solution was left stirring at RT overnight. After diluting with EtOAc, the organic phase was washed with NaOH (IN), water, brine, dried over Na₂SO4 and evaporated in vacuo to afford methyl 13-cyclohexyl-6-{[2-(dimethylamino)ethyl]amino}-6,7-dihydro5H-indolo[2,l-a][2] benzazepine-10-carboxylate. Hydrolysis of the foregoing methyl ester was done with IM aqueous KOH (6 eq) in dioxane (0. IM) at 60 °C; the reaction was complete in 2 h, and the title compound was obtained in 31% yield after RP-HPLC purification and lyophilisation (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 mm; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

*H NMR (400 MHz, DMSO, 300 K) δ 1.16-1.59 (4H, m), 1.61-2.12 (6H, m), 2.74-2-98 (8H, m), 3.123.43 (7H, m), 4.69-4.73 (1H, m), 7.49-7.58 (4H, m), 7.67-7.73 (1H, m), 7.90-7.93 (1H, m), 8.24 (1H, bs); MS (ES⁴) m/z 446.4 (M+H)⁺.

Example 6: Preparation of 13-cydohexyl-6-{[2-(dimethylamino)ethyl] [(methyl)amino]}-6,7dihydro-5/7-indolo[2,l-a][2]benzazepine-10-carboxylic acid

Methyl 13-cyclohexyl-6-{[2-(dimethylamino)ethyl]amino}-6,7-dihydro-5H-indolo[2,l-a][2]benzazepine10-carboxylate (prepared as in Example 5, Step 4) was dissolved in DCM (0.07 M) and pH adjusted to 6 with AcOH; 37% aq HCHO and, after half an hour NaCNBH₃ (3 eq), were added and the mixture was stirred at RT overnight. The reaction mixture was diluted with EtOAc and washed with IN NaOH and brine, dried and evaporated affording methyl 13-cyclohexyl-6-{[2-(dimethylamino)ethyl][(methyl) amino] }-6,7-dihydro-5//-indolo[2,l-a][2]benzazepine-10-carboxylate. Hydrolysis of the foregoing

WO 2006/046039

PCT/GB2005/004144 methyl ester was done with IM aqueous KOH (6 eq) in dioxane (0. IM) at 60 °C; the reaction was complete in 2 h, and the title compound was obtained in 20% yield after RP-HPLC purification and lyophilisation (Conditions: Column: Waters X-TERRA MS C18, 10 micron, 19 x 150 mm; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 75% A isocratic for 3 min, linear to 20% A in 12 min).

'H NMR (400 MHz, DMSO, 300 K) δ 1.16-1.59 (4H, m), 1.61-2.12 (6H, m), 2.74-2-98 (11H, m), 3.183.30 (1H, m), 3.50-3.69 (4H, m), 3.91-3.99 (1H, m), 4.21-4.30 (1H, m), 4.89-5.01 (1H, m), 7.39-7.58 (4H, m), 7.64-7.71 (1H, m), 7.92-7.99 (1H, m), 8.23-8.32 (1H, bs); MS (ES⁺) m/z 460.5 (M+H)⁺.

Example 7: Preparation of 12-cyclohexyl-4-(2-pyrrolidin-l-ylethoxy)-5,6-dihydro-4Hthieno[2',3':3,4]azepino[l,2-a]indole-9-carboxylic acid and 12-cyclohexyl-5-(2-pyrrolidin-lylethoxy)-5,6-dihydro-4/7-thieno[2',3':3,4]azepino[l,2-a]indole-9-carboxylic acid

Step 1: Methyl 3-cyclohexyl-2-(3-formyl-2-thienvl)-lH-indole-6-carboxylate

Methyl 2-bromo-3-cyclohexyl-l//-indole-6-carboxylate (prepared as described in published International patent application WO 2004/087714), (3-formyl-2-thienyl)boronic acid (1.2 eq), spray-dried KF (5 eq) and Pd(tBu₃P)₂ (0.2 eq) were dissolved in dioxane (0.15 M); the reaction mixture was stirred under N₂ at RT for 4 h, then more KF, boronic acid and catalyst were added and stirring was continued overnight. All volatiles were evaporated in vacuo and the title compound was isolated by flash chromatography (PE/EtOAc 8:2). Yield 99%; MS (ES*) m/z 368 (M+H)⁺.

Step 2: Methyl 3-cyclohexyl-2-(3-vinyl-2-thienyl)-lH-indole-6-carboxvlate

Tebbe reagent (0.5M in toluene) was added dropwise, at 0 °C to a 0.2M solution of methyl 3-cyclohexyl2-(3-formyl-2-thienyl)-lH-indole-6-carboxylate in dry THF; after 30 min the mixture was diluted with Et₂O and quenched with 0.1M aq NaOH. After 5 min Na₂SO₄ and Celite™ were added and the mixture filtered; the filtrate was concentrated in vacuo and the residue purified by flash chromatography (PE/EtOAc 10:1). Yield 34%; MS (ES⁺) m/z 366 (M+H)⁺.

Step 3: Methyl l-allyl-3-cyclohexyl-2-(3-vinyl-2-thienyl}-lH-indole-6-carboxylate

To a 0.1M solution of methyl 3-cyclohexyl-2-(3-vinyl-2-thienyl)-lH-indole-6-carboxylate in dry DMF, 60% NaH (1.2 eq) in mineral oil was added; when gas evolution had ceased, allyl bromide (1.4 eq) was added, and the suspension was stirred at RT for 30 min. All volatiles were evaporated and the title compound was isolated by flash chromatography (PE/EtOAc 10:1). Yield 77%.

‘H NMR (400 MHz, CDC1₃, 300 K) δ 1.28-1.90 (m, 10H), 2.60-2.69 (m, 1H), 3.97 (s, 3H), 4.52 (d_b, J 16.6, 1H), 4.63 (d_b, J 16.6, 1H),4.89 (d, J 17.2, 1H), 5.08 (d, J 10.1, 1H), 5.19 (d, J 11.1, lH),5.59(d,J 17.4, 1H), 5.76-5.84 (m, 1H), 6.35 (dd, J17.4, 11.1, 1H), 7.39-7.46 (m, 2H), 7.80 (d, 78.6, 1H), 7.84 (d, J 8.6, 1H), 8.08 (s, 1H).

WO 2006/046039

PCT/GB2005/004144

Step 4: Methyl 12-cyclohexyl-6H-thieno[2',3':3,4]azepinoi l,2-a]indole-9-carboxylate

Methyl l-allyl-3-cyclohexyl-2-(3-vinyl-2-thienyl)-lH-indole-6-carboxylate was dissolved in DCM (0.03M) and treated with Zhan catalyst I (5 mg per 100 mg of substrate) at 35 °C for 2 h. After removal of solvent the residue was purified by flash chromatography (PE/EtOAc 12:1) to afford the title compound (90%); MS (ES⁺) m/z 378 (M+H)⁺.

Step 5: 12-cyclohexyl-4-(2-vvrrolidm-1 -ylethoxy)-5,6-dihydro-4H-thieno[2',3':3,4lazepinofl,2-al indole9-carboxylic acid and 12-cvclohexyl-5-(2-pyrrolidin-l-vlethoxy)-5.6-dihvdro-4Hthienoi2',3':3,41 azepino i 1,2-alindole-9-carboxylic acid

BH₃ Me₂S (1.6 eq, 2M solution in THF) was added to a 0.1M solution of methyl 12-cyclohexyl-6Hthieno[2',3':3,4]azepino[l,2-a]indole-9-carboxylate in dry THF, and the mixture was stirred for 3 h at RT; 3M aq NaOH (3 eq) and 35% H₂O₂ (3.5 eq) were added at 0 °C, and stirring was continued for 2 h at RT. After dilution with EtOAc, the mixture was extracted with sat. aqueous NaHCOa and with brine. The organic phase was dried Na₂SO₄ and evaporated in vacuo to give a 4:1 mixture of methyl 12-cyclohexyl15 4-hydroxy-5,6-dihydro-477-thieno[2',3':3,4]azepino[l,2-a]indole-9-carboxylate and methyl 12cyclohexyl-5-hydroxy-5,6-dihydro-4H-thieno[2',3’:3,4]azepino[l,2-a]indole-9-carboxylate. This crude mixture was dissolved in toluene (0.07M), tetrabutylammonium bromide (0.25 eq) and 40% aq. NaOH (15 eq) were added, and the mixture was wanned to 70 °C. After stirring for half an hour at this temperature l-(2-chloroethyl)pyrrolidine hydrochloride (3 eq) was added and heating was continued at 70 °C for 2 days. All volatiles were evaporated in vacuo and the products isolated by RP-HPLC (combined overall yield 27%). (Conditions: Column: Waters X-TERRA MS C18, 7 um, 19 x 150 mm; Gradient: A: H₂O + 0.1% TFA; B: MeCN + 0.1% TFA; 99% A to 1% A in 15 min).

12-Cyclohexyl-4-(2-pyrrolidin-l-ylethoxy)-5,6-dihydro-4//-thieno[2',3':3,4]azepino[l,2-a]indole-9carboxylic acid (major): 'H NMR (400 MHz, DMSO, 300 K) δ 1.35-1.43 (m, 3H), 1.59-1.85 (m, 9H),

1.97-2.05 (m, 2H), 2.25-2.32 (m, 1H), 2.60-2.68 (m, 1H), 2.79-2.90 (m, 2H), 3.17-3.26 (m, 4H), 3.303.36 (m, 1H), 3.51-3.64 (m, 2H), 4.09-4.22 (m, 2H), 4.75 (t, J 6.14, 1H), 7.31 (d, J 5.26, 1H), 7.60 (dd, J 8.55, 1H), 7.77 (d, J 5.26, 1H), 7.85 (d, J 8.55, 1H), 8.14 (s, 1H), 9.44 (s_b, 1H); MS (ES⁺) m/z 479.4 (M+H)⁴.

12-Cyclohexyl-5-(2-pyrrolidin-l-ylethoxy)-5,6-dihydro-4H-thieno[2',3':3,4]azepino[l,2-a]indole-930 carboxylic acid (minor): *Η NMR (400 MHz, DMSO, 330 K) δ 1.27-1.38 (m, 3H), 1.69-2.32 (m, 11H), 2.57-2.62 (m, 1H), 3.03-3.18 (m, 4H), 3.38-3.56 (m, 4H), 3.85-3.90 (m, 1H), 3.94-4.00 (m, 1H), 4.034.08 (m, 1H), 4.31-4.35 (m, 2H), 7.20 (d, J 5.04, 1H), 7.63 (dd, J 8.55, 1H), 7.70 (d, J 5.05, 1H), 7.86 (d, J 8.55, 1H), 8.16 (s, 1H), 9.53 (s_b, 1H); MS (ES⁴) m/z 479.4 (M+H)⁴.

Example 8:14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[l,2e][l,5]benzodiazocine-ll-carboxylic acid

WO 2006/046039

PCT/GB2005/004144

Step 1: 3-[2-bromo-3-cyclohexyl-6-(methoxycarbonyl)-lH-indol-l-yl]propanoic acid

3.5 eq of NaH (60 % dispersion in mineral oil) was added to a solution of methyl 2-bromo-3-cyclohexyllH-indole-6-carboxylate (prepared as described in published International patent application WO 2004/087714, from commercially available methyl indole-6-carboxylate) in DMF (0.2 M) and the solution allowed to stir at RT for 1 h. Then 1.1 eq of 3-bromopropanoic acid were added and the mixture stirred at RT for 2 h. DMF was concentrated in vacuo and the residue taken up in EtOAc. The organic phase was washed with 1 N HC1 and then brine before being dried over Na2SO₄, filtered and the solvent evaporated in vacuo. The title compound was used crude in the next step; MS (ES⁺) m/z 408 (M+H)⁺, m/z 410 (M+H)⁺

Step 2: methyl 2-bromo-3-cyclohexyl-l-(3-methoxy-3-oxopropyl)-lH-indole-6-carboxylate

1.6 eq of (Trimethylsilyl)diazomethane (2 M solution in hexanes) was added dropwise to a solution of 3[2-bromo-3-cyclohexyl-6-(methoxycarbonyl)-lH-indol-l-yl]propanoic acid in a mixture toluene:MeOH (7:3; 0.2 M) and the solution allowed to stir at RT for 1 h. Excess (Trimethylsilyl)diazomethane was quenched with acetic acid and then the solution was concentrated in vacuo. The crude was purified by flash chromatography (Biotage cartridge Si40S, 1:9 EtOAc/PE) to afford the title compound in 63 % yield (over two steps). MS (ES⁺) m/z 422 (M+H)⁺, m/z 424 (M+H)⁺

Step 3: methyl 2-f2-[(tert-butoxvcarbonyl)aminolphenyl}-3-cyclohexyl-l-(3-methoxy-3-oxopropyl)-lHindole-6-carboxvlate

To a solution of methyl 2-bromo-3-cyclohexyl-l-(3-methoxy-3-oxopropyl)-lH-indole-6-carboxylate in dioxane (0.15 M) was added Na₂CO₃ (4 eq, 2 M aqueous solution), fert-butyl [2-(4,4,5,5-tetramethyll,3,2-dioxaborolan-2-yl)phenyl]carbamate (1.5 eq) and bis(triphenylphosphine)palladium(II) dichloride (0.2 eq). The mixture was heated at reflux for 45 mins. The reaction mixture was filtered and then the filtrate was diluted with EtOAc. The organic phase was washed with H₂O, brine and dried over Na₂SO₄before being filtered and concentrated in vacuo. The crude was purified by flash chromatography (Biotage cartridge Si65i, 1:9 EtOAc/PE) to give the title compound as a white solid (60 %); MS (ES⁺) m/z 535 (M+H)⁺.

Step 4: 3-[2-f2-[(tert-butoxvcarbonyl)amino]phenyl}-3-cvclohexvl-6-(methoxycarbonyl)-lH-indol-lyllpropanoic acid

1.1 eq of lithium hydroxide monohydrate was added to a solution of methyl 2-{2-[(tert-butoxycarbonyl) amino]phenyl}-3-cyclohexyl-l-(3-methoxy-3-oxopropyl)-lH-indole-6-carboxylate in a mixture THF:H₂O (4:1; 0.1 M). The mixture was stirred at RT for 1.5 h. The reaction was quenched with 1 N HC1 and the solvent evaporated in vacuo. The residue was washed with the minimum amount of Et₂O and the

WO 2006/046039

PCT/GB2005/004144 resultant precipitate filtered to obtain the title compound as a white solid (81 %); MS (ES⁴) m/z 521 (M+H)⁺. .

Step 5: 3-f2-(2-aminophenyl)-3-cyclohexyl-6-(methoxycarbonyl)-lH-indol-l-yl]propanoic acid

To a solution of 3-[2-{2-[(tert-butoxycarbonyl)amino]phenyl}-3-cyclohexyl-6-(methoxycarbonyl)-lHindol-l-yl]propanoic acid in DCM (0.05 M) a large excess (&gt; 100 eq) of TFA was added and the solution was stirred at RT for 1 h. The volatiles were removed in vacuo to afford the title compound (quant); MS (ES⁺) m/z 421 (M+H)⁺.

Step 6: methyl 14-cyclohexyl-6-oxo-5,6.7,8-tetrahydroindolofl,2-elU.51benzodiazocine-ll-carboxylate To a solution of 3-[2-(2-aminophenyl)-3-cyclohexyl-6-(methoxycarbonyl)-lH-indoI-l-yl]propanoic acid in DCM (0.01 M), 3.5 eq of DIPEA and 1.2 eq of HATU were added and the mixture was stirred at RT for 15 mins. DCM was removed in vacuo, the residue was taken up in acetone and IN HC1 was added until pH=2. The resulting precipitate was filtered and dried to give the product in 75 % yield; MS (ES⁺) m/z 403 (M+H)⁺.

Step 7: methyl 14-cyclohexyl-5-f2-(dimethylamino)ethyll-6-oxo-5.6,7.8-tetrahydroindolofl.2e][ 1,5 lbenzodiazocine-11-carboxylate

NaH (1.4 eq, 60 % dispersion in mineral oil) was added to a solution of methyl 14-cyclohexyl-6-oxo5,6,7,8-tetrahydroindolo[l,2-e][l,5]benzodiazocine-ll-carboxylate in DMF (0.1 M) and the solution allowed to stir at RT for 1 h. In the meantime, a 1:1 equimolar mixture of (2-chloroethyl)dimethylamine hydrochloride and NaH (60 % dispersion in mineral oil) in solution in DMF (0.5 M) was prepared. After 30 mins, this mixture (2.5 eq of (2-chloroethyl)dimethylamine) was slowly added to the solution of indole anion and the mixture was stirred at RT overnight. DMF was removed in vacuo and the residue taken up in EtOAc. The organic phase was washed with H₂O (twice) and then brine before being dried over Na₂SO₄, filtered and the solvent evaporated in vacuo. The crude compound was used in the next step without further purification; MS (ES⁺) m/z 474 (M+H)⁺.

Step 8: 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolof 1,2e] f 1,5 lbenzodiazocine-11 -carboxylic acid

To a solution of methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[l,2e][l,5]benzodiazocine-l 1-carboxylate in DCM (0.1M) 7 eq BBr₃ (IM solution in DCM) were added. The solution stirred at RT for 20 mins. The volatiles were evaporated in vacuo. The crude was then purified by prep RP-HPLC (stationary phase: column Waters XTERRA prep. C18, 5 um, 19 x 150 mm. Mobile phase: MeCN/H₂O buffered with 0.1% TFA). Fractions containing the pure compound were combined and freeze dried to afford the title compound (40 % over two steps).

WO 2006/046039

PCT/GB2005/004144 'H NMR (400 MHz, DMSO-d₆, 300 K) δ 1.10-1.35 (m, 3H), 1.50-1.60 (m, 1H), 1.60-1.75 (m, 2H), 1.802.00 (m, 4H), 2.40-2.45 (m, 1H partially obscured by DMSO peak), 2.70 (s, 6H), 2.72-2.80 (m, 2H), 2.903.15 (m, 2H), 3.20-3.40 (m, 1H obscured by H₂O peak), 3.61-3.75 (m, 1H), 3.80-3.90 (m, 1H), 4.75-4.85 (m, 1H), 7.53-7.58 (m, 1H), 7.60-7.68 (m, 3H), 7.69-7.75 (m, 1H), 7.86 (d, J 8.4, 1H), 8.14 (s, 1H), 9.27 (br s, 1H); MS (ES⁺) m/z 460 (M+H)⁺.

Example 9:14-cyclohexyl-5-[2-(dimethylamino)ethyI]-5,6,7,8-tetrahydroindolo[l,2e][l,5]benzodiazocine-lbcarboxylic acid

To a solution of methyl 14-cyclohexyl-5-[2-(dimethylamino)ethyl]-6-oxo-5,6,7,8-tetrahydroindolo[l,2e][l,5]benzodiazocine-11-carboxylate (prepared as described in Example 8, Step 7) in THF (0.1 M), BH₃.Me₂S (20 eq, 2 M solution in THF) was added. The solution was stirred overnight at RT. MeOH was carefully added to the mixture to quench the reaction, followed by an excess of 1 N NaOH (&gt; 10 eq). The mixture was heated at 60 °C for 12 h. The solvent was evaporated in vacuo. The crude was then purified by prep RP-HPLC (stationary phase: column Waters XTERRA prep. C18, 5 um, 19 x 100 mm. Mobile phase: MeCN/H₂0 buffered with 0.1% TFA). Fractions containing the pure compound were combined and freeze dried to afford the title compound (24 % over three steps).

Ή NMR (300 MHz, DMSO-d₍₅+ TFA, 300 K) δ 1.15-1.40 (m, 3H), 1.50-1.58 (m, 1H), 1.60-1.75 (m, 3H), 1.80-2.00 (m, 5H), 2.55-2.65 (m, 1H), 2.74 (s, 3H), 2.78 (s, 3H), 2.90-3.10 (m, 2H), 3.10-3.30 (m, 4H), 3.55-3.65 (m, 1H), 4.50-4.65 (m, 1H), 6.95-7.01 (m, 1H), 7.10-7.20 (m, 2H), 7.35-7.45 (m, 1H), 7.64 (d, J 8.2, 1H), 7.84 (d, J 8.2, 1H), 8.09 (s, 1H); MS (ES⁺) m/z 446 (M+H)⁺.

Example 10:14-cyclohexyl-5-methyl-5,6,7,8-tetrahydroindolo[l,2-e][l,5]benzodiazocine-llcarboxylic acid

Step 1: methyl 14-cyclohexyl-5,6,7,8-tetrahydroindolo[ 1,2-el [ 1.5]benzodiazocine-l 1 -carboxylate

To a solution of methyl 14-cyclohexyl-6-oxo-5,6,7,8-tetrahydroindolo[l,2-e][l,5]benzodiazocine-llcarboxylate (prepared as described in Example 8, Step 6) in THF (0.15 M), 20 eq of BH₃.Me₂S (2 M sol. in THF) were added and the mixture was stirred at RT for 6 h. The solution was carefully quenched by adding MeOH until effervescence subsided. The volatiles were then evaporated in vacuo. The crude residue was used directly in the next step; MS (ES⁺) m/z 389 (M+H)⁺.

Step 2: methyl 14-cvclohexyl-5-methvl-5,6,7,8-tetrahydroindolof 1,2-elI 1,5lbenzodiazocine-l 1carboxylate

To a solution of methyl 14-cyclohexyl-5,6,7,8-tetrahydroindolo[l,2-e][l,5]benzodiazocine-llcarboxylate in DCE (0.05 M) 1 eq of formaldehyde (37 wt. % sol. in H₂O) and 2 eq of NaBH(OAc)₃ were added and the solution stirred at RT for 1 h. The reaction mixture was diluted with EtOAc. The organic

WO 2006/046039

PCT/GB2005/004144 phase was washed with NaHCO₃ (s.s.) and brine. The organic phase was dried over Na₂SO₄ filtered and concentrated in vacuo. The title compound was used directly in the next step; MS (ES⁺) m/z 403 (M+H)⁺.

Step 3: 14-cyclohexvl-5-methyl-5,6,7,8-tetrahydroindolo[ 1,2-el i 1.5 Jbenzodiazocine-11 -carboxylic acid To a solution of methyl 14-cyclohexyl-5-methyl-5,6,7,8-tetrahydroindolo[l,2-e][l,5]benzodiazocine-llcarboxylate in DCM (0.1 M), 5 eq of BBr₃ (IM sol. in DCM) were added. The solution was stirred at RT for 20 mins. The solvent was evaporated in vacuo. The crude was then purified by automated prep RP-HPLC (stationary phase: column Waters XTERRA prep. C18, 5 um, 19 x 100 mm. Mobile phase: MeCN/H₂O buffered with 0.1% TFA). Fractions containing the pure compound were combined and freeze dried to afford the title compound (60 % over two steps).

*H NMR (400 MHz, DMSO-d₆+ TFA, 300 K) 8 1.10-1.60 (m, 5H), 1.60-1.80 (m, 2H), 1.80-2.10 (m, 5H), 2.65-2.75 (m, 2H), 2.85-2.95 (m, 1H), 2.98 (s, 3H), 3.55-3.68 (m, 1H), 4.55-4.65 (m, 1H), 6.65-6.75 (m, 1H), 6.84 (d, J 8.4, 1H), 7.03 (d, J 7.6, 1H), 7.27-7.32 (m, 1H), 7.63 (d, J 8.4, 1H), 7.81 (d, J 8.4, 1H), 8.08 (s, 1H), MS (ES⁴) m/z 389 (M+H)⁴.

Example 11:14-cyclohexyl-7-(dimethyIamino)-5-methyI-5,6,7,8-tetrahydroindolo[l,2-e][l,5] benzodiazocine-11 -carboxylic acid

Step 1: methyl 2-fbis(tert-butoxycarbonyl)aminol acrylate

To a solution of methyl 7V-(rer/-butoxycarbonyl)serinate in MeCN (0.9 M) were added 2.5 eq of di-tertbutyl dicarbonate and 0.1 eq of DMAP. The solution was stirred at RT for 48 h, before being quenched with saturated aqueous NaHCO₃ and extracted (twice) with EtOAc. The combined organics were washed with saturated aqueous NH4CI and brine before being dried over Na₂SO₄, filtered and concentrated in vacuo to give the title compound as a cream solid (quantitative); MS (ES⁺) m/z 324 (M+Na)⁺.

Step 2: methyl l-f2-[bis(tert-butoxycarbonyl)aminol-3-methoxy-3-oxopropyll-2-bromo-3-cvclohexvl-lHindole-6-carboxylate

To a solution of methyl 2-bromo-3-cyclohexyl-l//-indole-6-carboxylate (prepared as described in WO 2004087714 from commercially available methyl indole-6-carboxylate) in MeCN (0.08 M) were added 6 eq of K₂CO₃ and 1.2 eq of methyl 2-[bis(ierZ-butoxycarbonyl)amino]acrylate. The mixture was stirred at RT for 16 h before being filtered and concentrated in vacuo to afford the title compound as a viscous oil which solidified on standing (quantitative); MS (ES⁴) m/z 659 (M+Na)⁺, 661 (M+Na)⁴.

Step 3: methyl 2-bromo-l-{2-f(tert-butoxycarbonyl)aminol-3-methoxy-3-oxopropyll-3-cyclohexyl-IHindole-6-carboxylate

To a solution of methyl l-{2-[bis(ieri-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}-2-bromo-3cyclohexyl-lH-indoIe-6-carboxylate in CH₂C1₂ (0.15 M), were added 2 eq of TFA. The solution was

WO 2006/046039

PCT/GB2005/004144 stirred at RT for 10 mins before being concentrated in vacuo. RP-HPLC analysis of the reaction mixture showed about 50 % deprotection of the Boc amine. The residue was redissolved in CH₂C1₂ and a further 2 eq of TFA added. After stirring for 10 mins at RT, the volatiles were again removed in vacuo. This time RP-HPLC showed that complete mono-deprotection of the amine had occurred (quantitative); MS (ES⁺) m/z 559 (M+Na)⁺, 561 (M+Na)⁺.

Step 4: 3-[2-(2-aminophenyl)-3-cvclohexyl-6-(methoxycarbonyl)-lH-indol-l-yll-N-(tertbutoxycarbonyl (alanine

To a solution of methyl 2-bromo-l-{2-[(rer/-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}-3cyclohexyl-lH-indole-6-carboxylate in nBuOH:H₂O (9:1, 0.08 M) were added 1.5 eq of 2-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)aniline, 6 eq of K₃PO₄, 5 mol % of dicyclohexyl(2',6'dimethoxybiphenyl-2-yl)phosphine and 2.5 mol % of palladium acetate. The mixture was heated at 90 °C for 4 h. After cooling to RT, the mixture was acidified with HC1 (IN) and extracted (twice) with EtOAc. The combined organics were washed with brine and dried over Na₂SO₄ before being filtered and concentrated in vacuo. The crude product mixture was redissolved in THF:H₂O (1:1, 0.08 M) and 2 eq LiOH added. After stirring for 1 h, ester deprotection was complete as evidenced by RP-HPLC analysis. The volatiles were removed in vacuo and the residue partitioned between EtOAc and H₂O. The organics were washed with brine and dried over Na₂SO₄ before being filtered and concentrated in vacuo. The crude residue was used directly in the next step; MS (ES⁺) m/z 536 (M+H)⁺, 558 (M+Na)⁺.

Step 5: methyl 7-i(tert-butoxycarbonyl}amino]-14-cvclohexyl-6-oxo-5.6.7.8-tetrahydroindoloi 1.2e][l,51 benzodiazocine-11 -carboxylate

To a solution of 3-[2-(2-aminophenyl)-3-cyclohexyl-6-(methoxycarbonyl)-lH-indol-l-yl]-N-(tertbutoxycarbonyl)alanine in CH₂C1₂ (0.02 M) were added 3 eq of iPr₂NEt and 1.2 eq of HATU and the mixture stirred at RT for 16 h. The reaction was quenched with saturated aqueous NaHCO₃ and extracted (twice) with EtOAc. The combined organics were washed with HC1 (IN) and brine before being dried over Na₂SO₄, filtered and concentrated in vacuo. The crude was purified by flash chromatography (5 20 % EtOAc/1 % Et₃N/PE) to afford the title compound as an oil in 12 % yield (3 steps); MS (ES⁺) m/z 518 (M+H)⁺, 540 (M+Na)⁺.

Step 6: methyl 7-f(tert-butoxvcarbonyl)amino]-14-cyclohexvl-5.6.7.8-tetrahydroindolo fl.2e][ 1,5 ] benzodiazocine-11 -carboxylate

To a solution of methyl 7-[(teri-butoxycarbonyl)amino]-14-cyclohexyl-6-oxo-5,6,7,8-tetrahydroindolo [l,2-e][l,5]benzodiazocine-ll-carboxylate in THF (0.02 M), 10 eq of BH₃.THF (2 M solution in THF) were added and the mixture was stirred at RT for 4 h. All volatiles were removed under reduced pressure and the crude residue was used directly in the next step; MS (ES⁺) m/z 504 (M+H)⁺, 526 (M+Na)⁺.

WO 2006/046039

PCT/GB2005/004144

Step 7: methyl 7-amino-14-cyclohexyl-5,6.7,8-tetrahydroindoloil,2-elil,5l benzodiazocine-11carboxylate

To a solution of methyl 7-[(Ze/7-butoxycarbonyl)amino]-14-cyclohexyl-5,6,7,8-tetrahydroindolo [1,2e][l,5]benzodiazocine-l 1-carboxylate in CH₂C1₂ (0.02 M), was added 100 eq of TFA. The solution was stirred at RT for 45 mins before being concentrated in vacuo to afford the product as a viscous oil (quantitative); MS (ES⁺) m/z 404 (M+H)*

Step 8: methyl 14-cyclohexyl-7-(dimethylamino)-5-methyl-5,6.7.8-tetrahydroindoloil.2e][ 1,5 Ibenzodiazocine-11 -carboxylate

To a solution of methyl 7-amino-14-cyclohexyl-5,6,7,8-tetrahydroindolo[l,2-e][l,5] benzodiazocine-11carboxylate in CH₂C1₂ (0.02 M) were added 5 eq of formaldehyde (37 % in H₂O) and the pH adjusted to pH 4 with triethylamine. The solution was stirred at RT for 30 mins before addition of 3 eq of NaBH₃CN and the mixture stirred at RT for 16 h. The reaction was quenched with saturated aqueous NaHCO₃ and extracted (twice) with EtOAc. The combined organics were washed with brine before being dried over Na₂SO₄, filtered and concentrated in vacuo to give the title compound as a viscous oil (quantitative); MS (ES⁺) m/z 446 (M+H)*.

Step 9: 14-cyclohexyl-7-(dimethylamino)-5-methyl-5.6,7.8-tetrahydroindololl,2-elfl,51 benzodiazocinell-carboxylic acid

To a solution of methyl 14-cyclohexyl-7-(dimethylamino)-5-methyl-5,6,7,8-tetrahydroindolo[l,2e][l,5]benzodiazocine-l 1-carboxylate in MeOH (0.05 M), 40 eq 2N NaOH were added and the reaction stirred at 65 C for 3 h. The reaction was acidified to pH 2 with HC1 and the solvent was evaporated in vacuo. The crude was then purified by prep RP-HPLC (stationary phase: column Waters XTERRA prep. C18, 5 um, 19 xl50 mm. Mobile phase: acetonitrile/H₂O buffered with 0.1 % TFA). Fractions containing the pure compound were combined and freeze dried to afford the title compound as a brown powder in 8 % yield (over four steps).

'H NMR (400 MHz, DMSO-d_tf + TFA, 300 K) δ 1.15-1.34 (m, 3H), 1.54-1.94 (m, 7H), 2.62-2.68 (m, 1H), 2.86 (s, 3H), 2.96 (s, 6H), 3.13-3.17 (m, 1H), 3.36-3.41 (m, 1H), 3.59-3.62 (m, 1H), 3.88-3.94 (m, 1H), 4.93-4.98 (m, 1H), 7.00-7.03 (m, 1H), 7.13-7.15 (m, 2H), 7.42-7.46 (m, 1H), 7.72 (d, J 8.3, 1H), 7.86 (d, J 8.3, 1H), 8.29 (s, 1H); MS (ES*) m/z 432 (M+H)*.

The following table contains further examples:

WO 2006/046039

PCT/GB2005/004144

Table 1

<td> Example no.</td><td> Name</td><td> m/z (ES⁺)</td>

<td> 101</td><td> 13-cyclohexyl-5-[2-(dimethylamino)ethoxy] -6,7-dihydro-5ZZ-indolo[2,1 a] [2] benzazepine-10-carboxy 1 ic acid</td><td> 447</td>

<td> 102</td><td> 13-cyclohexy 1-5 -[2-(diethylamino)ethoxy] -6,7-dihydro-5/7-indolo[2,1 a][2]benzazepine-1 O-carboxylic acid</td><td> 475</td>

<td> 103</td><td> 13-cyclohexyl-6-[2-(diethylamino)ethoxy]-6,7-dihydro-5H-indolo[2,la][2]benzazepine-10-carboxylic acid</td><td> 475</td>

<td> 104</td><td> 13-cyclohexyl-3-methoxy-6-(2-pyrrolidin-1 -ylethoxy)-6,7-dihydro-5Hindolo[2,1 -a] [2] benzazepine-1 O-carboxylic acid</td><td> 503</td>

<td> 105</td><td> 13-cyclohexyl-3-methoxy-5-(2-pyrrolidin-l-ylethoxy)-6,7-dihydro-5Hindolo[2,1 -a] [2] benzazepine-1 O-carboxylic acid</td><td> 503</td>

2005298412 11 May 2011